We are a clinical-stage biopharmaceutical company focused on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. Our lead product candidate, THB001, is a highly selective, oral small molecule inhibitor of KIT, a cell surface receptor that acts as the master survival and functional regulator of mast cells. […]

We are a holding company with no material operations of our own. We conduct our operations in China through our variable interest entity (VIE), Taizhou Kepui Communication Equipment Co. Ltd., or Taizhou Kepuni in the People’s Republic of China (PRC). (Incorporated in the Cayman Islands) Taizhou Kepuni Communication Equipment Co., Ltd. is a high-tech enterprise integrating […]

(Note: Midwest Energy Emissions Corp. withdrew its plans for a NASDAQ uplisting from the OTC markets in an SEC filing dated Aug. 24, 2022. The company filed its S-1 for the NASDAQ uplisting/public offering on Nov. 10, 2021; no terms were filed. A reverse stock split had been planned as part of the public offering […]

(New Beginnings Acquisition Corp. II withdrew its SPAC IPO on Aug. 22, 2022. The S-1 was filed on April 7, 2021.) We intend to initially focus on companies in the travel, hospitality, leisure, financial technology (FinTech), insurance technology and property technology (PropTech) sectors in the United States. Russell W. Galbut, our chairman, has over 34 years […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB Market, where the common stock trades under the symbol “TOWTF”. The company’s common stock also trades on the Canadian Securities Exchange (“CSE”) under the symbol “TO”, and the Frankfurt Stock Exchange (the “FRA”) under the symbol “1P3N”. A reverse share split […]

(Note: This IPO is an initial public offering of common stock – under the proposed symbol “LIPO” – for listing on the NASDAQ – plus one non-tradeable, non-listed warrant to buy a share of common stock.) We are a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic […]

(Note: This is a unit IPO. Felicitex Therapeutics Inc. revised the terms of its unit IPO in an S-1/A filing dated Oct. 31, 2022, by changing the composition of the units. Each unit now consists of one share of common stock and two warrants – each to buy one share of common stock. The Oct. […]

We intend to focus our search for target companies on financial technology (FinTech) and property technology (PropTech) businesses in the Nordic region and the Asia Pacific (APAC) region, especially the South Pacific.  These target companies will include businesses that offer technology solutions, technology software, services or products to the financial services or real estate industries where […]

We are a holding company. (Incorporated in the British Virgin Islands)  As a holding company with no material operations, our operations are conducted by our indirect wholly owned subsidiary, Global Engine Limited (“GEL”), in Hong Kong, a special administrative region of the People’s Republic of China (the “PRC”). This is an offering of the Ordinary Shares […]

Note: EMulate Therapeutics withdrew its plans for an IPO in a letter to the SEC dated July 31, 2024. The biotech filed confidentially for an IPO in May 2022 and followed up with its S-1 filing in August 2022. EMulate Therapeutics filed terms for its small-cap IPO on Jan. 4, 2023. We are on a mission […]